In order to strengthen business operations in India, which is expected to experience high economic growth, Japan's Shimadzu Corporation will establish the manufacturing subsidiary Shimadzu Manufacturing India Private Limited (SMI) in Bengaluru, Karnataka. Construction of the new plant is scheduled to be completed and operations are to be started in the spring of 2027.
In addition to the business areas where Shimadzu is focusing efforts, namely healthcare, green innovation, materials, and industry, India is also a global manufacturer of generic drugs and is expected to continue increasing domestic production of electric vehicles (EVs) and semiconductors.
Currently, Shimadzu products are supplied to India from Japan or Shimadzu Malaysia Sdn. Bhd. (SML) in Malaysia. Building the new plant will not only strengthen the supply chain but also respond to governmental incentives for domestic production (“Make in India”).
SMI will begin manufacturing liquid chromatograph (LC), gas chromatograph (GC), UV-VIS spectrophotometer (UV), liquid chromatograph mass spectrometer (LC-MS), and gas chromatograph mass spectrometer (GC-MS) products in 2027.
In addition to analytical and measuring instruments, future manufacturing of medical systems and industrial machinery products are also being considered.
Similarly, Shimadzu also plans to merge the analytical and measuring instruments and medical systems sales subsidiaries in India to establish Shimadzu India Private Limited (SIP) by the summer of 2025.
The new sales subsidiary SIP will be a wholly-owned subsidiary of Shimadzu (Asia Pacific) Pte. Ltd. (SAP) in Singapore, Shimadzu’s regional headquarters for the Asia region, making SIP an indirect subsidiary of Shimadzu Corporation. The analytical and measuring instruments sales subsidiary in India was established in 2005 and the medical systems sales subsidiary in 2001. Both have been engaged in sales and service activities, but will now integrate their operations to form the new company SIP. Operating both businesses as a single organization will strengthen relationships with hospitals and other customers that use both medical and analytical/measuring systems and will help Shimadzu deploy business in clinical fields and increase customer satisfaction by supplying solutions.
By establishing the new manufacturing subsidiary SMI and the new sales subsidiary SIP, Shimadzu plans to achieve about 47.0 billion yen in sales in India by FY2035 (about 2.6 times the FY2023 level).
